SYNOLIS VA 80/160
DeviceSYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
NCT Number: NCT05829733
Multicenter, independent study of Synolis VA 80/160 over a period of 6 months
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Service de Rhumatologie, Hôpital Nord Franche-Comté, Belfort, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
Time frame: 6 months (M6)
Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.
Time frame: Month 3, Month 3 to Month 6
Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.
Time frame: Month 3, Month 3 to Month 6
7-point Likert scale (-3 to +3)
Time frame: Month 3, Month 3 to Month 6
Minimum clinically important difference on the Oxford Hip Score (OXFORD 12)
Time frame: Month 6
Number of Participants with Hip prosthesis placement
Time frame: Month 6
Serious adverse event occurrence
Contact information is provided by the study sponsor or research team.
Aptissen SA
Industry
6-month Evaluation of the Efficacy and Safety of Synolis VA 80/160 in the Treatment of Symptomatic Hip Osteoarthritis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06145516
Arthritis, Dyssomnias
Uppsala, Uppland, Sweden
View Trial DetailsNCT07069179
Arthritis, Behavior
Vancouver, British Columbia, Canada
View Trial DetailsNCT03711773
Arthralgia, Arthritis
Columbia, Missouri, United States
View Trial DetailsNCT05278520
Arthritis, Arthritis, Rheumatoid
Turku, Southwest Finland, Finland
View Trial Details